

# CD Bioparticles Announces Carrageenans for Scientific Applications

*CD Bioparticles has recently announced the launch of its Carrageenans for various applications such as drug delivery, food, and cosmetics.*

SHIRLEY, NEW YORK, UNITED STATES, April 26, 2023 /EINPresswire.com/ -- [CD Bioparticles](#), a leading manufacturer and supplier of numerous drug delivery products and services, has recently announced the launch of its [Carrageenans](#) for various applications such as drug delivery, food, and cosmetics.

Carrageenan (CG) is a sulfated linear polysaccharide composed of D-galactose and 3,6-anhydro-D-galactose derived from certain red seaweeds of the Rhodophyceae family, e.g. Agardhiella, Chondrus crispus, Eucheuma, Furcellaria, Gigartina, Hypnea, Iridaea, Sarconema, and Solieria.

The use of carrageenan was first described in Ireland in the early 19th century. In recent years, carrageenan-based biomaterials have received considerable attention due to their versatility, including biodegradability, biocompatibility and non-toxicity, as well as their bioactive properties, such as antiviral, antibacterial, antihyperlipidemic, anticoagulant, antioxidant, antitumor and immunomodulatory properties. They have been utilized in pharmaceutical formulations because their bioactive and physicochemical properties make them suitable biomaterials for drug delivery and, more recently, for the development of tissue engineering.

CD Bioparticles now offers a range of carrageenans, such as alfa-Carrageenan, iota-Carrageenan, Type II, and kappa-Carrageenan for drug delivery and pharmaceutical researchers. In addition, as a supplier of biocompatible drug delivery systems, CD Bioparticles also supplies various biodegradable polymers for research usage, such as Dextrans, Chitosans, Heparins, and Dendrimers, enabling scientists to overcome challenges, e.g., uncontrollable drug delivery profiles, limited ability to bioconjugate between macromolecules and biomolecules, unpredictable or uncontrolled degradation rates of drug-loaded cargos, tedious chemical synthesis and purification, and denaturation of biomolecules during the conjugation.

## Features

Extensive coverage of biomaterials with different physical properties such as Tg, Tm, shear viscosity, Young's modulus, and dielectric constant to meet individual biomaterial processing conditions and end-product requirements.

Various functionalized biomolecules to facilitate custom conjugation, modification, and crosslinking applications.

Precise formulation of polymer composition and controlled degradation time for various drug delivery and biografting applications.

Effective conjugation reactions at ambient conditions to prevent protein denaturation.

Temperature-dependent solubility of biomaterials in aqueous solutions with controlled transition temperatures, such as different UCST and LCST.

"We're committed to providing our customers with the highest quality technology and service to help them achieve the most reliable experimental results. As carrageenan continues to advance in laboratory testing and practical processing, we'll assist researchers in unlocking the full value and potential of this biodegradable polymer." said Robin J. Watts, Ph.D., the scientific director of research and development at CD Bioparticles. "We're confident that our continued support of researchers and their projects will accelerate their research process and help them make additional pharmaceutical advances."

For more information about carrageenans or other transfection products, please visit CD Bioparticles at <https://www.cd-bioparticles.net/>.

#### About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Richard J. Gray

CD Bioparticles

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/630104203>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.